.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Nevirapine - Generic Drug Details

« Back to Dashboard
Nevirapine is the generic ingredient in three branded drugs marketed by Aurobindo, Sandoz Inc, Alvogen Malta, Apotex Inc, Mylan Pharms Inc, Boehringer Ingelheim, Prinston Inc, Cipla Ltd, Cipla, Mylan Labs, Sciegen Pharms Inc, Micro Labs Ltd, Hetero Labs Ltd Iii, and Strides Pharma, and is included in twenty NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has twenty-nine patent family members in twenty-five countries.

There are twenty drug master file entries for nevirapine. Nineteen suppliers are listed for this compound. There are seven tentative approvals for this compound.

Summary for Generic Name: nevirapine

Tradenames:3
Patents:1
Applicants:14
NDAs:20
Drug Master File Entries: see list20
Suppliers / Packaging: see list19
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices

Tentative approvals for NEVIRAPINE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL50MG
<disabled><disabled>TABLET; ORAL200MG
<disabled><disabled>TABLET; ORAL200MG
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
VIRAMUNE
nevirapine
SUSPENSION;ORAL020933-001Sep 11, 1998RXYes► subscribe► subscribe
Prinston Inc
NEVIRAPINE
nevirapine
TABLET;ORAL078644-001May 22, 2012RXNo► subscribe► subscribe
Micro Labs Ltd
NEVIRAPINE
nevirapine
TABLET;ORAL203080-001May 22, 2012RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: nevirapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
VIRAMUNE
nevirapine
SUSPENSION;ORAL020933-001Sep 11, 19985,366,972*PED► subscribe
Boehringer Ingelheim
VIRAMUNE XR
nevirapine
TABLET, EXTENDED RELEASE;ORAL201152-001Mar 25, 20115,366,972*PED► subscribe
Boehringer Ingelheim
VIRAMUNE
nevirapine
TABLET;ORAL020636-001Jun 21, 19965,366,972*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: nevirapine

Country Document Number Estimated Expiration
Uruguay31128► subscribe
South Africa200904939► subscribe
World Intellectual Property Organization (WIPO)2008154234► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEVIRAPINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90022Netherlands► subscribePRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223
C0021Belgium► subscribePRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223
C0019France► subscribePRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc